Abbott Japan

• NCT01479127

  Collaborator, Phase 2, Completed, 8 people, 24 Nov 2011

• Distinct metabolomic signatures of SGLT2 inhibitor vs. sulfonylurea in a paired human liver biopsy study

  Grants or research support, 14 Sept 2026

• Tirzepatide Benefit for Early Glycemic and Weight Management in People with T2D in Japan: Rationale, Design, and Baseline Characteristics of T-BEAT Study

  Fees or honoraria, 8 Sept 2026

• Nutrition Clinical Framework, Mortality, and Length of Stay Among Older Inpatients With Malnutrition

  Fees or honoraria, Grants or research support, 1 Sept 2026

• Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study

  Grants or research support, 14 Aug 2026

• Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial

  Fees or honoraria, 13 Aug 2026

Sources: pubmed.ncbi.nlm.nih.gov

• Five-Year Changes in Glucose Tolerance, Insulin Secretion, and Insulin Resistance in Community-Dwelling Older Adults

  ADA Scientific Sessions 2025 abstract, 13 Jun 2025